Hydroxyethyl starch
April 7, 2014
The Therapeutic Goods
Administration (TGA) has
published a safety advisory about
hydroxyethyl starch, used in clinical
situations and contained in two
Australian Register of Therapeutic
Goods listed products, Voluven and
Volulyte.
The TGA said a safety review
found an increased risk of mortality
and need for dialysis when the
medicine was used to treat patients
with sepsis.
The TGA said it had worked
with sponsor Fresenius Kabi to
update the product information
for the medicines, including new
contraindications for patients with
sepsis and severe liver disease,
as well as updated information
in the precautions, dosage and
administration sections.
These updates were sufficient to
mitigate identified risks, the TGA
said - to read more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 14
